Drugs pricing policy questioned
Poor implementation of a policy aimed at better value for PBS spending is costing the government $320 million a year, according to a Grattan Institute report.
It shows that the therapeutic group premium policy, which applies to drugs that are chemically different, but interchangeable in their impact, “has been so watered down it no longer works”, write Stephen Duckett (pictured) and Peter Breadon.
They raise questions about pharmaceutical industry involvement in drug pricing.
While they say the policy introduced